Ipsen Press Releases | Latest News & Updates

Topics

Period

Filter by

Reset

Showing: 1 – 5 of 248 Press Releases

Show

Sort

13 July 2026

13 July 2026

Download IQIRVO® demonstrates statistically significant improvement in ALP normalization in patients with PBC in Phase IIIb ELSPIRE study

IQIRVO® demonstrates statistically significant improvement in ALP normalization in patients with PBC in Phase IIIb ELSPIRE study

09 July 2026

09 July 2026

Download Dysport® is the first botulinum toxin to achieve positive topline Phase III results in both episodic and chronic migraine.

Dysport® is the first botulinum toxin to achieve positive topline Phase III results in both episodic and chronic migraine.

01 July 2026

01 July 2026

Download Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio

29 June 2026

29 June 2026

Download Ipsen to acquire Kartos Therapeutics, expanding hemato-oncology late-stage pipeline

Ipsen to acquire Kartos Therapeutics, expanding hemato-oncology late-stage pipeline

15 June 2026

15 June 2026

Download IPSEN - Buy-back programme - Art 5 of MAR - Week 24 - 2026

IPSEN – Buy-back programme – Art 5 of MAR – Week 24 – 2026

Your dedicated contacts

Media Relations

+33 1 58 33 50 00

IpsenMediaRelations@ipsen.com

Add to contacts

Stay updated

Register to receive our latest news